DEPTOR expression negatively correlates with mTORC1 activity and tumor progression in colorectal cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 11, 2014, Pages 4589-4594

  Lai, Er Yong ^a   Chen, Zhen Guo ^b   Zhou, Xuan ^b   Fan, Xiao Rong ^b   Wang, Hua ^b   Lai, Ping Lin ^b   Su, Yong Chun ^b   Zhang, Bai Yu ^c   Bai, Xiao Chun ^b   Li, Yun Feng ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Colorectal cancer; DEPTOR; Immunohistochemistry; mTOR; P S6

Indexed keywords

DEPTOR PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; CELL DIFFERENTIATION; COLORECTAL TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENETICS; HUMAN; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR INVASION; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; NEOPLASM INVASIVENESS; PROGNOSIS; TOR SERINE-THREONINE KINASES; UP-REGULATION; YOUNG ADULT;

EID: 84903710857     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.11.4589     Document Type: Article

References (37)

1. Baldo P, Cecco S, Giacomin E, et al (2008). mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets, 8, 647-65.
2. Bijnsdorp IV, Peters GJ (2011). Deoxyribose protects against rapamycin-induced cytotoxicity in colorectal cancer cells in vitro. Nucleosides Nucleotides Nucleic Acids, 30, 1197-202.
3. Bjornsti MA, Houghton PJ (2004). The TOR pathway: a target for cancer therapy. Nat Rev Cancer, 4, 335-48.
4. Bruneau S, Nakayama H, Woda CB, Flynn EA, Briscoe DM (2013). DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood, 122, 1833-42.
5. Cai Z, Ke J, He X, et al (2014). Significance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer. Ann Surg Oncol, 21, 179-88.
6. Edge, SB, Compton CC (2010). The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17, 1471-4.
7. Fasolo A, Sessa C (2012). Targeting mTOR pathways in human malignancies. Curr Pharm Des, 18, 2766-77.
8. Finn RS (2012). Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition. Liver Cancer, 1, 247-56.
9. Friedrichs K, Gluba S, Eidtmann H, Jonat W (1993). Overexpression of p53 and prognosis in breast cancer. Cancer, 72, 3641-7.
10. Guertin DA, Sabatini DM (2007). Defining the role of mTOR in cancer. Cancer Cell, 12, 9-22.
11. Hay N, Sonenberg N (2004). Upstream and downstream of mTOR. Genes Dev, 18, 1926-45.
12. Huang GL, Guo HQ, Yang F, et al (2012). Activating transcription factor 1 is a prognostic marker of colorectal cancer. Asian Pac J Cancer Prev, 13, 1053-7.
13. Huh JW, Kim HR, Kim YJ, et al (2009). Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int, 59, 241-6.
14. Iwaya T, Yokobori T, Nishida N, et al (2012). Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis, 33, 2391-7.
15. Jacobs BL, Goodman CA, Hornberger TA (2013). The mechanical activation of mTOR signaling: an emerging role for late endosome/lysosomal targeting. J Muscle Res Cell Motil, [Epub ahead of print].
16. Kunimura T, Yoshida T, Suqiyama T, Morohoshi T (2009). The Relationships Between Loss of Standard CD44 Expression and Lymph Node, Liver Metastasis in T3 Colorectal Carcinoma. J Gastrointest Cancer, 40, 115-8.
17. Li ZT, Zhang L, Gao XZ, Jiang XH, Sun LQ (2013). Expression and significance of the Wip1 proto-oncogene in colorectal cancer. Asian Pac J Cancer Prev, 14, 1975-9.
18. Lyzogubov V, Khozhaenko Y, Usenko V, et al (2005). Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer. Exp Oncol, 27, 141-4.
19. Martelli AM, Evangelisti C, Follo MY, et al (2011). Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem, 18, 2715-26.
20. Meng ZX, Li S, Wang L, et al (2013). Baf60c drives glycolytic metabolism in the muscle and improves systemic glucose, 2014 4594 homeostasis through Deptor-mediated Akt activation. Nat Med, 19, 640-5.
21. Migliardi G, Sassi F, Torti D, Trusolino L, Bertotti A (2012). Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res, 18, 2515-25.
22. Mueller S, Phillips J, Onar-Thomas A, et al (2012). PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol, 14, 1146-52.
23. Nelson LD, Bender C, Mannsperger H, et al (2012). Triplex DNA-binding proteins are associated with clinical outcomes revealed by proteomic measurements in patients with colorectal cancer. Mol Cancer.
24. Ostendorff HP, Awad A, Braunschweiqer KI, et al (2013). Multiplexed veracode bead-based serological immunoassay for colorectal cancer. J Immunol Methods, 400-401, 58-69.
25. Pandurangan AK (2013). Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev, 14, 2201-5.
26. Peterson TR, Laplante M, Thoreen CC, et al (2009). DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell, 137, 873-86.
27. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-101.
28. Sarkar S (2013). Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. Biochem Soc Trans, 41, 1103-30.
29. Sisik A, Kaya M, Bas G, Basak F, Alimoglu O (2013). CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients. Asian Pac J Cancer Prev, 14, 4289-94.
30. Sun YX, Mao X, Xie L, et al (2013). Differential Activation of mTOR Complex 1 Signaling in Human Brain with Mild to Severe Alzheimer's Disease. J Alzheimers Dis, 38, 437-44.
31. Wang D, Chen J, Guo F, et al (2011). Clinical significance of mTOR and p-mTOR protein expression in human colorectal carcinomas. Asian Pac J Cancer Prev, 12, 2581-4.
32. Wang Z, Zhong J, Inuzuka H, et al (2012). An evolving role for DEPTOR in tumor development and progression. Neoplasia, 14, 368-75.
33. Yang YF, Zhang XY, Yang M, et al (2014). Prognostic role of nucleophosmin in colorectal carcinomas. Asian Pac J Cancer Prev, 15, 2021-6.
34. Ye C, Kiriyama K, Mistuoka C, et al (1995). Expression of E-selectin on endothelial cells of small veins in human colorectal cancer. Int J Cancer, 61, 455-60.
35. Zhang HR, Chen JM, Zeng ZY, Que WZ (2013). Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. J Int Med Res, 41, 584-95.
36. Zhao GT, Yang LJ, Li XX, Cui HL, Guo R (2013). Expression of the proto-oncogene Pokemon in colorectal cancer--inhibitory effects of ansiRNA. Asian Pac J Cancer Prev, 14, 4999-5005.
37. Zhao Y, Xiong X, Sun Y (2011). DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell, 44, 304-16.